Key Points
- Insider Mayukh Sukhatme sold a total of about 1.36 million shares in December (including 311,873 shares on Dec. 29 for ~$6.78M and 1,018,995 shares on Dec. 31 for ~$22.12M), generating roughly $29.5 million in proceeds.
- Despite the sales, Sukhatme still directly owned 19,273,032 shares after the Dec. 29 transaction (valued at ~$419M), the Dec. 29 sale representing a 1.59% reduction in his stake.
- Roivant shares are trading near their 12‑month high (around $21.70), the company has a market cap of about $15.1B, and analysts hold a consensus "Moderate Buy" with a target near $25.19.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 311,873 shares of the stock in a transaction on Monday, December 29th. The shares were sold at an average price of $21.74, for a total transaction of $6,780,119.02. Following the transaction, the insider directly owned 19,273,032 shares in the company, valued at approximately $418,995,715.68. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Mayukh Sukhatme also recently made the following trade(s):
- On Wednesday, December 31st, Mayukh Sukhatme sold 1,018,995 shares of Roivant Sciences stock. The stock was sold at an average price of $21.71, for a total transaction of $22,122,381.45.
- On Wednesday, December 17th, Mayukh Sukhatme sold 26,831 shares of Roivant Sciences stock. The stock was sold at an average price of $23.09, for a total transaction of $619,527.79.
Roivant Sciences Trading Up 0.3%
Shares of Roivant Sciences stock opened at $21.70 on Thursday. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $23.47. The firm has a market capitalization of $15.09 billion, a PE ratio of -38.75 and a beta of 1.22. The firm's 50-day moving average price is $20.80 and its 200 day moving average price is $15.71.
Wall Street Analysts Forecast Growth
ROIV has been the subject of several research reports. JPMorgan Chase & Co. boosted their price target on Roivant Sciences from $16.00 to $20.00 and gave the stock an "overweight" rating in a research report on Thursday, September 18th. Bank of America upped their target price on shares of Roivant Sciences from $12.00 to $16.50 and gave the stock a "neutral" rating in a report on Thursday, September 18th. Leerink Partners increased their target price on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, December 15th. Guggenheim restated a "buy" rating and set a $28.00 price target on shares of Roivant Sciences in a research report on Thursday, December 18th. Finally, HC Wainwright upped their price objective on shares of Roivant Sciences from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $25.19.
Get Our Latest Stock Report on ROIV
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ROIV. Rubric Capital Management LP grew its holdings in shares of Roivant Sciences by 14.7% in the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company's stock valued at $229,574,000 after purchasing an additional 2,603,260 shares during the period. State Street Corp boosted its holdings in Roivant Sciences by 4.8% in the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company's stock valued at $222,847,000 after purchasing an additional 911,827 shares during the last quarter. Two Seas Capital LP grew its stake in shares of Roivant Sciences by 4.6% in the 2nd quarter. Two Seas Capital LP now owns 10,598,040 shares of the company's stock valued at $119,440,000 after buying an additional 461,733 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Roivant Sciences by 18.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 9,308,710 shares of the company's stock valued at $140,839,000 after buying an additional 1,423,074 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of Roivant Sciences by 12.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,506,400 shares of the company's stock worth $50,787,000 after buying an additional 506,219 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
